Sitravatinib in Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer Stage IV|Triple Negative Breast Cancer|Breast Neoplasms|Breast Cancer Metastatic
Interventions: DRUG: Sitravatinib
Sponsor: C. Kent Osborne, MD
Collaborators: Mirati Therapeutics Inc.